



South Korea and Australia on the rise as clinical research hubs

Novotech's vice president highlighted the APAC region's growing clinical presence, drawing attention to Australia and South Korea.

Akosua Mireku | June 12, 2024

Share <



Credit: AimPix via Shutterstock. Dr. Yooni Kim, Novotech's vice president of clinical services, highlights Australia and South Korea as attractive clinical research bases due to supportive public frameworks.

Dr. Yooni Kim, the vice president of clinical services at Novotech, says Australia and South Korea are emerging as bubbling clinical research hubs in the [Asia-Pacific \(APAC\) region](#).



Free Whitepaper Navigating the FDA Approval Processes: Capitalize on Regulatory Expertise to Simplify the Complex

Over the last 10 years, the total cost to develop a pharmaceutical asset has more than doubled. This whitepaper outlines the global approval landscape, including pathways to approval and typical impediments to success. Download now for guidance on formulating a...

[Read more](#) ▾

By Novotech

At the ongoing [Outsourcing in Clinical Trials UK and Ireland conference](#), Kim led a session on "Unlocking APAC potential to enhance your clinical program." The event, held 11 - 12 June, gathered clinical trial professionals to debate issues within the sector. At Kim's talk, she highlighted the 142 European biotech companies that have conducted single-country or multinational clinical trials in the [APAC region](#) between 2019 and 2023, saying that the region has become the "fastest-growing global market for pharmaceutical sales".

In particular, Kim highlighted [South Korea's](#) "attractive" government frameworks for clinical research. For example, the Korea Health Industry Development Institute (KHIDI) has created a national artificial intelligence (AI) platform that integrates data from several healthcare institutes to support clinical trials, match patients with studies, and monitor trial progress. Moreover, Samsung Medical Center is also growing partnerships with AI startups for data analysis and patient outreach, she adds.

Partner Content



The future of eClinical technology interoperability: Have your say

A new survey from GlobalData aims to gain insights into deploying new

By Viedoc Technoloaies

Go deeper with GlobalData

Reports
Impact of South Korea on the Pharmaceutical Industry - Thematic Int...

Reports
Clinical Trials Sector Scorecard, Q2 2022 Update - Thematic Research

Data Insights
The gold standard of business intelligence.

[Find out more](#) >

What is your company's sentiment toward proposed higher tariffs?

- ☐ Very positive
- ☐ Somewhat positive
- ☐ Neutral
- ☐ Somewhat negative
- ☐ Very negative

Submit

Poll • 162 Responses

GlobalData

"Australia also has a very streamlined process," says Kim, calling attention to the region's six – eight-week trial start-up timeline for private sites. This includes the period needed for an application to go from an Ethics committee submission to approval. Furthermore, the country does not require a clinical trial application (CTA) or an investigational new drug (IND) application to conduct a study. Several biotech companies begin clinical trials in Australia as they simultaneously prepare US IND submissions, and choose to run their earlier phase studies in Australia before transitioning to the US for the later stages, said Kim. This makes the country particularly attractive as the US agencies accept clinical data from Australia for subsequent regulatory submissions, she adds.

Partner Content



The future of eClinical technology interoperability: Have your say

A new survey from GlobalData aims to gain insights into deploying new

By Viedoc Technologies

In 2024, the Australian government initiated its Clinical Trials Activity Initiative that aimed to provide \$750m over 10 years between 2024/2025 and 2033/2034. The government plans to aid clinical trials addressing rare cancers, rare diseases, unmet needs, and bring investigator-led international clinical studies to Australia, as per the government website. The country has been taking actions to improve its global appeal as a clinical research superpower for several years, introducing a research and development (R&D) refund scheme with up to 43.5% cash refunds that was launched in July 2021.



Free Whitepaper

Navigating the FDA Approval Processes: Capitalize on Regulatory Expertise to Simplify the Complex

Over the last 10 years, the total cost to develop a pharmaceutical asset has more than doubled. This whitepaper outlines the global approval landscape, including pathways to approval and typical impediments to success. Download now for guidance on formulating a...

[Read more](#)

By Novotech

Enter your work email

First name *

Last name *

Company name *

Job title *

Country Code *

Phone number *

Country *

☐ I'm not a robot



By downloading this Whitepaper, you acknowledge that GlobalData may share your information with [Novotech](#) and that your personal data will be used as described in their [Privacy Policy](#)

Submit

Visit our [Privacy Policy](#) for more information about our services, how GlobalData may use, process and share your personal data, including information on your [Privacy Policy](#) for more information about our services, how GlobalData

may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.



Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.

[Sign up](#)

Share

Pharmaceutical Technology

The leading site for news and procurement in the pharmaceutical industry



[About us](#)

[Advertise with us](#)

[License our content](#)

[Contact us](#)

[Editorial approach](#)

[Newsletters](#)

[Our marketing solutions](#)

[Privacy policy](#)

[Terms and conditions](#)

[Sitemap](#)

Powered by **VERDICT**

© Verdikt Media Limited 2025

